| abstract |
Composition and methods for characterizing cancer cells by determining a marker of PKM2 activity. For example, methods are provided for predicting a patient response to a NF- κB, PKCε, PKM2, MEK/ERK, Pinl or Src inhibitor therapy. Methods for treating patients with such therapies are likewise provided. Phosphorylation selective β-catenin, MLC2, histone H3, Bub3, and PKM2 -binding antibodies are also provided. |